Ki-67 expression stratifies PD-L1-high NSCLC for immune checkpoint inhibitor plus chemotherapy: a real-world biomarker validation
Cancer Immunology, Immunotherapy · 2025
DOI: 10.1007/s00262-025-04207-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Ning Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, General Hospital of Southern Theater Command, No. 111 Liuhua Road, Guangzhou, 510010, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Immune Checkpoint Inhibitors, Ki-67 Antigen, Lung Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Basic and Applied Basic Research Program of Guangdong Province, Key Clinical Research Project of the General Hospital of Southern Theater Command.
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND: For patients with programmed death-ligand 1 (PD-L1)-high non-small cell lung cancer (NSCLC), both immune checkpoint inhibitor (ICI) monotherapy and ICI plus chemotherapy are first-line options, yet optimal subgroups for each remain undefined. We evaluated Ki-67 expression as a biomarker for treatment stratification. METHODS: We retrospectively analyzed 334 advanced PD-L1-high NSCLC cases (2018-2024). Patients were stratified by Ki-67 expression, and outcomes with ICI monotherapy versus ICI-chemotherapy were compared using propensity score matching and multivariable Cox models. RESULTS: After propensity score matching, in the Ki-67 > 30% cohort (n = 166), ICI-chemotherapy was associated with a higher ORR versus ICI monotherapy (32/83, 38.6% vs. 17/83, 20.5%; P = 0.01) and with longer PFS (9.9 vs. 8.4 months; HR 0.51, 95% CI 0.37-0.72; P < 0.001) and OS (22.1 vs. 16.5 months; HR 0.47, 95% CI 0.32-0.70; P < 0.001). In the Ki-67 ≤ 30% cohort (n = 78), ORR was identical (9/39, 23.1%), and no improvement was observed for PFS (8.3 vs. 9.1 months; HR 1.59, 95% CI 0.98-2.59; P = 0.06) or OS (15.7 vs. 20.3 months; HR 1.47, 95% CI 0.85-2.54; P = 0.16). Patients receiving ICI-chemotherapy had more grade ≥ 3 adverse events (40/157, 25.5% vs. 24/177, 13.6%), predominantly hematologic (30/157, 19.1% vs. 3/177, 1.7%). CONCLUSION: Ki-67 expression may represent a potential predictive biomarker for identifying PD-L1-high NSCLC patients more likely to benefit from chemo-immunotherapy, though its clinical utility requires confirmation in prospective, randomized studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, General Hospital of Southern Theater Command, No. 111 Liuhua Road, Guangzhou, 510010, China.
- Graduate School, Guangzhou University of Chinese Medicine, Guangzhou, China.
- Department of Oncology, General Hospital of Southern Theater Command, No. 111 Liuhua Road, Guangzhou, 510010, China. xiebodoctor@163.com.
- Graduate School, Guangzhou University of Chinese Medicine, Guangzhou, China. xiebodoctor@163.com.
- The First School of Clinical Medicine, Southern Medical University, Guangzhou, China. xiebodoctor@163.com.
- Department of Oncology, General Hospital of Southern Theater Command, No. 111 Liuhua Road, Guangzhou, 510010, China. juanzhn@163.com.
Förderung
- Basic and Applied Basic Research Program of Guangdong Province
- Key Clinical Research Project of the General Hospital of Southern Theater Command
Zitieren
APA
Yang, N., Chen, X., Wang, H., Liu, P., Liu, B., Xie, B., & Zhou, J. (2025). Ki-67 expression stratifies PD-L1-high NSCLC for immune checkpoint inhibitor plus chemotherapy: a real-world biomarker validation. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-04207-9
Vancouver
Yang N, Chen X, Wang H, Liu P, Liu B, Xie B, et al. Ki-67 expression stratifies PD-L1-high NSCLC for immune checkpoint inhibitor plus chemotherapy: a real-world biomarker validation. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-04207-9
BibTeX
@article{Yang2025,
author = {Yang, Ning and Chen, Xiting and Wang, Haoqiang and Liu, Peng and Liu, Baiyang and Xie, Bo and Zhou, Juan},
title = {Ki-67 expression stratifies PD-L1-high NSCLC for immune checkpoint inhibitor plus chemotherapy: a real-world biomarker validation},
journal = {Cancer Immunology, Immunotherapy},
year = {2025},
doi = {10.1007/s00262-025-04207-9}
}
EUVIMED